28 September 2023

Blenheim has advised the shareholders of Bonusan on the partnership with bd-capital

Category: Mergers and acquisitions

Blenheim is proud to announce that is has advised the shareholders of Bonusan on the partnership with bd-capital. Arjen Paardekooper, Dirk de Waard and Olivier Bergh advised the shareholders on this deal.

Bonusan chooses partnership with bd-capital to accelerate realization of its ambitions

Bonusan is a healthcare company with 120 years’ experience in food supplements with formulations based on science and insights gained from healthcare professionals. Four generations of the Bogaerds family have created an authority in the market of food supplements, driven by passion and entrepreneurship.

Demand for personalised healthcare solutions continues to grow rapidly on the back of increasing focus on preventative healthcare and an ageing population. Bonusan’s mission is to access this growth by providing more people with access to its knowledge, its network of healthcare professionals and its high-quality, science-based products.

Search for a partner who would support the growth of the business

The Bogaerds family initiated the search for a partner who would support the growth of the business while sharing their vision of maintaining the high-quality standards of Bonusan’s products. The partnership with bd-capital will allow Bonusan and the Natura Foundation, its education and training platform for healthcare professionals, to increase their reach and make more of a positive impact on health and wellbeing for consumers across Europe. bd-capital attributes great significance to the Bonusan history, its value-add to healthcare professionals and their clients, and the important role of the Natura Foundation as a leading training institute and knowledge centre in its field.

Rik Boagaerds commented: “we are very pleased to announce our partnership with bd-capital, allowing us to increase our relevance to current and future customers and partners. The partnership increases our potential to invest in R&D and innovation and will enable us to enlarge the reach of our products, services, and training programs. We share the same values and strategic objectives, and together with our customers and partners we can apply our joint expertise to have a positive influence on the health and wellbeing of an ever-increasing number of people.”